Clinical trials · Nashville, TN
Advanced or Metastatic Solid Tumors clinical trials in Nashville
We’re tracking 338 recruiting advanced or metastatic solid tumors studies with a site in or near Nashville — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Nashville
- NCT05118789RecruitingPhase 1/Phase 2
Study drug for ROS1-positive lung or solid tumors
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Nashville, TennesseeAges 12 years+ - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
Nashville, TennesseeAges 18 years+ - NCT06736704RecruitingPhase 1/Phase 2
Study of SNV4818 for advanced solid tumors with PIK3CA mutation
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT06118086RecruitingPhase 1/Phase 2
Study of REM-422 for advanced adenoid cystic carcinoma
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
Nashville, TennesseeAges 18 years+ - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Nashville, TennesseeAges 18 years+ - NCT05941507RecruitingPhase 1/Phase 2
TROP2 antibody drug with anti–PD-1 for advanced solid tumors
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
Nashville, TennesseeAges 18 years+ - NCT04913285RecruitingPhase 1
KIN-2787 for advanced solid tumors with BRAF or NRAS mutations
This trial tests a new drug, KIN-2787, for people with advanced solid tumors that have specific changes (mutations) in the BRAF or NRAS genes. The drug is designed to target these changes and may help shrink or control the tumor.
Nashville, TennesseeAges 18 years+ - NCT04660760RecruitingPhase 2
Comparing two treatments for advanced stomach cancer after first treatment
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Nashville, TennesseeAges 18 years+ - NCT05573126RecruitingPhase 1/Phase 2
Study of EP0062 for advanced breast cancer with AR+ and ER+
This Phase 1/2 study tests EP0062, a study medicine given alone or with other treatments, in people with advanced or metastatic breast cancer. It’s designed to see how well it works and what side effects it causes when the cancer has specific hormone-receptor markers (AR+ and ER+) and is HER2-negative.
Nashville, TennesseeAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Nashville, TennesseeAges 18 years+ - NCT06330064RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
Nashville, TennesseeAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Nashville, TennesseeAges 18 years+ - NCT06179160RecruitingPhase 1
Study of INCB161734 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
Nashville, TennesseeAges 18 years+ - NCT07751042RecruitingPhase 1/Phase 2
Study of STX-003 with and without pembrolizumab for advanced solid tumors
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
Nashville, TennesseeAges 18 years+ - NCT03947385RecruitingPhase 1/Phase 2
First drug test for metastatic uveal melanoma with specific gene changes
This Phase 1/2 trial studies IDE196 in adults with metastatic uveal melanoma that has certain gene mutations or fusions. It’s mainly testing safety and correct dosing, and may help shrink tumors in patients matched to the tumor’s genetic changes.
Nashville, TennesseeAges 18 years+ - NCT06644781RecruitingPhase 3
Study of Ifinatamab Deruxtecan for advanced esophageal cancer
This trial tests a new drug, Ifinatamab Deruxtecan, for people with advanced esophageal squamous cell carcinoma that has worsened after standard treatments. It aims to see if it can help shrink or slow the cancer.
Nashville, TennesseeAges 18 years+ - NCT04142437Recruiting
Tracking how larotrectinib works for NTRK fusion cancers in routine care
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
Nashville, TennesseeAges Any age - NCT06188520RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors in women
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
Nashville, TennesseeAges 18 years+ - NCT06950034RecruitingPhase 1
Testing STX-0712 for advanced CMML or AML
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
Nashville, TennesseeAges 18 years+ - NCT06952010RecruitingPhase 1
Study of XB628 alone and with zanzalintinib for advanced solid tumors
This trial tests a new drug, XB628, alone or together with another drug called zanzalintinib, in people whose advanced solid tumor has continued to grow after at least one prior treatment. The goal is to see if these combinations can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT05433142RecruitingPhase 1
XmAb 819 for advanced kidney cancer and other solid tumors
This Phase 1 trial tests a new drug called XmAb 819 to treat advanced clear cell kidney cancer and other cancers that have grown despite standard treatments. It mainly looks at safety and how the body responds, with the goal of finding signs the drug can work.
Nashville, TennesseeAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Nashville, TennesseeAges 18 years+ - NCT06940739RecruitingPhase 1/Phase 2
IOV-3001 and lifileucel for advanced melanoma
This trial tests a new combination treatment, IOV-3001 and lifileucel, for people with advanced melanoma that has not responded to standard immunotherapy and cannot be surgically removed. It aims to see if this cellular therapy is safe and effective.
Nashville, TennesseeAges 18–70 - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Nashville, TennesseeAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near Nashville, TN
We’ll email you when one opens near Nashville, TN — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Nashville
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Sarah Cannon Research Institute · 7 studies
- Vanderbilt University Medical Center · 4 studies
- Research Site · 3 studies
- SCRI Oncology Partners · 3 studies
- Tennessee Oncology · 2 studies
- Exelixis Clinical Site #3
- GSK Investigational Site
- Sarah Cannon Research Institute-Tennessee Oncology
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in Tennessee.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near Nashville?
- Yes. We're currently tracking 338 recruiting advanced or metastatic solid tumors studies with a site near Nashville, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near Nashville?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Nashville to take part?
- Not necessarily. These studies have a site near Nashville, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near Nashville regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.